Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

This is a public health crisis that exacerbates overdiagnosis and threatens the sustainability of health systems,” said Ray Moynihan, PhD.

Researchers evaluated links between lifestyle and dietary index scores and risk of death in a prospective, multiethnic cohort of men diagnosed with non-metastatic prostate cancer.

HHS Secretary Robert F. Kennedy Jr. has rescinded the HHS policy of requiring new rules and regulations to be open to public comment before they are implemented.

Researchers are projecting that, worldwide, new cases of female breast cancer will increase 38% by 2050, and female breast cancer deaths will increase 68%. These projections and other data were ...

Though President Trump denied having any connection to Project 2025 on the campaign trail, he has pushed its health policy ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.

Dr Francis Collins, the famed geneticist who led the National Institutes of Health for 12 years, has stepped down.

Using AI-enabled tools to automatically deny more and more needed care is not the reform of prior authorization physicians and patients are calling for,” said AMA President Bruce A. Scott, MD.

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.